The ALDH16A1 Knockout HeLa Polyclonal Cells are a HeLa-derived polyclonal knockout population generated via CRISPR/Cas9-mediated disruption of the ALDH16A1 gene. This polyclonal format provides a heterogeneous pool of edited cells suitable for population-level studies of ALDH16A1 loss-of-function, minimizing clonal selection biases. The model is designed for investigating aldehyde dehydrogenase biology in cervical adenocarcinoma epithelial cells, with applications in cancer metabolism and detoxification research.
The HeLa cell line, a human cervical adenocarcinoma-derived epithelial model, is widely used for its robust growth and genetic tractability. HeLa cells retain key tumor microenvironment features, including altered metabolic dependencies and stress responses, making them an ideal background for gene editing studies. Using HeLa cells for ALDH16A1 knockout allows examination of aldehyde dehydrogenase function within oncogenic transformation and metabolic rewiring contexts.
ALDH16A1 encodes an NAD+-dependent aldehyde dehydrogenase that oxidizes aldehydes to carboxylic acids, crucial for detoxification. It is transcriptionally regulated by Nrf2 (activated by oxidative stress) and PPAR??, linking its activity to redox balance and metabolic signaling. Downstream, ALDH16A1 modulates aldehyde metabolite clearance and cellular NAD+ levels, interacting with NAD+ cofactor and cross-talking with ALDH1A1, ALDH2, and CYP450 enzymes. CRISPR/Cas9 disruption abolishes enzymatic function, causing aldehyde accumulation and metabolic stress, observable through downstream effectors and stress pathways.
In the cervical adenocarcinoma background, ALDH16A1 knockout disrupts aldehyde detoxification, sensitizing cells to endogenous aldehydes and oxidative stress. The loss of ALDH16A1-mediated NAD+ regeneration alters the NAD+/NADH ratio, affecting glycolysis and mitochondrial function. This makes the knockout cells valuable for studying metabolic stress adaptation and resistance to aldehyde-generating chemotherapeutics. The interplay with Nrf2 and PPAR?? further illuminates how cancer cells coordinate detoxification and survival.
Typical applications include cancer cell metabolism, drug resistance, and detoxification pathway analysis. Aldehyde dehydrogenase activity assays and Aldefluor flow cytometry quantify functional ALDH activity, while Western blot and RT-qPCR confirm ALDH16A1 ablation and monitor compensatory changes in ALDH1A1, ALDH2, or Nrf2. MTT assays under aldehyde stress (e.g., 4-hydroxynonenal, acetaldehyde) evaluate cytotoxicity. These cells also enable ALDH inhibitor screening. For further details, contact Ascent Research.
